期刊文献+

连续3年临床分离鲍曼不动杆菌临床分布及耐药性 被引量:27

Clinical distribution and antimicrobial resistance of Acinetobacter baumannii isolated from patients in consecutive three years
下载PDF
导出
摘要 目的分析某院鲍曼不动杆菌感染现状及耐药性变迁,指导临床用药,为控制医院感染提供相关的科学依据。方法对该院2011年1月—2013年12月临床分离的鲍曼不动杆菌引起的感染分布及药敏检测结果进行回顾性分析。结果 3年共分离鲍曼不动杆菌339株,主要标本来源为痰液,共检出291株,占85.84%;其次尿标本分离29株(8.55%),分泌物标本分离12株(3.54%),血液标本分离3株(0.89%)。主要分布科室为重症监护室(ICU)分离149株(43.95%);其次呼吸内科46株(13.57%),儿科32株(9.44%),肿瘤科22株(6.49%)。鲍曼不动杆菌对妥布霉素、亚胺培南有较好的药物敏感性(耐药率11.11%-49.47%),对其他抗菌药物的耐药率较高;2012年和2013年的耐药率明显低于2011年。结论该院临床分离的鲍曼不动杆菌主要来源于痰标本,多分布于ICU和呼吸科;对抗菌药物耐药率高,但近年有下降趋势。 Objective To analyze the clinical distribution and antimicrobial resistance of Acinetobacter baumannii (A.baumannii)from a hospital,so as to guide the rational use of antimicrobial agents and provide scientific basis for the prevention and control of healthcare-associated infection(HAI).Methods Distribution and antimicrobial susceptibility testing results of A.baumannii isolated from patients between January 2011 and December 2013 were analyzed retrospectively.Results A total of 339 A.baumannii isolates were isolated within three years,291 iso-lates (85.84%)were from sputum,followed by urine (n=29,8.55%),secretion(n=12,3.54%)and blood (n=3,0.89%).The main distribution departments were intensive care unit(ICU,n=149,43.95%),department of re-spiratory medicine (n=46,13.57%),department of pediatrics (n =32,9.44%)and oncology (n =22,6.49%). The resistant rate of A.baumannii to tobramycin and imipenem were 11 .11 %-49.47%,the resistant rates to the other antimicrobial agents were relatively high;antimicrobial resistant rate of 2012 and 2013 were obviously lower than 2011 .Conclusion A.baumannii from this hospital are mainly from sputum specimens,and mainly distribute in ICU and department of respiratory medicine,antimicrobial resistant rate is high,but there is a decreasing tenden-cy in recent years.
作者 周燕飞 邓敏
出处 《中国感染控制杂志》 CAS 北大核心 2015年第1期42-44,共3页 Chinese Journal of Infection Control
基金 2014年武汉市公共卫生及卫生政策科研项目(WG14C12)
关键词 鲍曼不动杆菌 医院感染 耐药性 抗药性 微生物 多重耐药菌 抗菌药物 Acinetobacter baumannii healthcare-associated infection drug resistance drug resistance,microbi-al multidrug-resistant bacteria antimicrobial agent
  • 相关文献

参考文献11

二级参考文献46

共引文献1282

同被引文献274

  • 1焦炳华,穆军,许强芝,缪辉南.海洋微生物来源新抗生素的研究[J].抗感染药学,2004,1(1):1-9. 被引量:29
  • 2江惟苏,陈荣,谭升顺,陈庆秀.特比萘芬与氟康唑或伊曲康唑体外联合抗白念珠菌的作用[J].中国抗生素杂志,2005,30(9):568-571. 被引量:7
  • 3骆俊,吴菊芳,朱德妹,李光辉,张婴元,汪复.上海市华山医院血流感染患者的病原学和临床研究[J].中华传染病杂志,2006,24(1):29-34. 被引量:40
  • 4王瑶,徐英春.2004—2005年中国CHINET鲍曼不动杆菌耐药性分析[J].中国感染与化疗杂志,2007,7(4):279-282. 被引量:71
  • 5中华人民共和国卫生部.医疗机构消毒技术规范[s].2012.
  • 6中华人民共和国卫生部.WS/T311-2009医务人员手卫生规范[S].北京,2009.
  • 7CLSI. Performance standards for antimicrobial susceptibility testing twentieth informational supplement, M100-S21 [S]. Wayne, PA : Clinical and Laboratory Standards Institute,2011.
  • 8Fouad M, Attia AS, Tawakkol WM, et al. Emergence of carbap- enem-resistant Acinetobacter baumannii harboring the OXA-23 carbapenemase in intensive care units of Egyptian hospitals [J]. Int J InfecDis, 2013, 17(12): e1252-1254.
  • 9Eser OK, Ergin A, Tunckanat F, Hascelik G. In vitro activi- ty of tigecyeline as a therapeutic option against multidrug-re- sistant Acinetobacter spp. [J]. New Microbiol, 2008, 31 (4) : 535 - 542.
  • 10Aygi3n G, Demirkiran O, Utku T,et al. Environmental con- tamination during a carbapenem-resistant Acinetobacter bau- mannii outbreak in an intensive care unit[J]. J Hosp Infect, 2002, 52(4): 259-262.

引证文献27

二级引证文献210

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部